Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Niesen

Showing results (71-80 of 81) with videos related to

Pageof 9
Sort By:
Journal of Managed Care & Specialty Pharmacy|August 30, 2025
Impact of empirical treatment failure on health care resource utilization and costs among female patients with uncomplicated urinary tract infections in a US-based Integrated Health Delivery NetworkJeffrey J Ellis, Anushree Iyengar, Hari Bandi, et al.
The Lancet. Digital Health|March 24, 2023
Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysisRobert P Matson, Michiel J M Niesen, Emily R Levy, et al.
Med (New York, N.Y.)|July 5, 2021
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health systemColin Pawlowski, Patrick Lenehan, Arjun Puranik, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalenceArjun Puranik, Patrick J Lenehan, Eli Silvert, et al.
NPJ Systems Biology and Applications|November 28, 2024
A deep learning approach predicting the activity of COVID-19 therapeutics and vaccines against emerging variantsRobert P Matson, Isin Y Comba, Eli Silvert, et al.
PNAS Nexus|January 30, 2023
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infectionMichiel J M Niesen, Robert Matson, Arjun Puranik, et al.
PNAS Nexus|July 14, 2022
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19Arjun Puranik, Patrick J Lenehan, John C O'Horo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditionsPritha Ghosh, Michiel J M Niesen, Colin Pawlowski, et al.
Iscience|July 31, 2024
Case-control study on post-COVID-19 conditions reveals severe acute infection and chronic pulmonary disease as potential risk factorsPritha Ghosh, Michiel J M Niesen, Colin Pawlowski, et al.
Med (New York, N.Y.)|December 20, 2021
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infectionArjun Puranik, Patrick J Lenehan, Eli Silvert, et al.
Pageof 9

Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Journal of Managed Care & Specialty Pharmacy|August 30, 2025
Impact of empirical treatment failure on health care resource utilization and costs among female patients with uncomplicated urinary tract infections in a US-based Integrated Health Delivery NetworkJeffrey J Ellis, Anushree Iyengar, Hari Bandi, et al.
The Lancet. Digital Health|March 24, 2023
Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysisRobert P Matson, Michiel J M Niesen, Emily R Levy, et al.
Med (New York, N.Y.)|July 5, 2021
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health systemColin Pawlowski, Patrick Lenehan, Arjun Puranik, et al.
Medrxiv : the Preprint Server for Health Sciences|August 17, 2021
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalenceArjun Puranik, Patrick J Lenehan, Eli Silvert, et al.
NPJ Systems Biology and Applications|November 28, 2024
A deep learning approach predicting the activity of COVID-19 therapeutics and vaccines against emerging variantsRobert P Matson, Isin Y Comba, Eli Silvert, et al.
PNAS Nexus|January 30, 2023
Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infectionMichiel J M Niesen, Robert Matson, Arjun Puranik, et al.
PNAS Nexus|July 14, 2022
Durability analysis of the highly effective BNT162b2 vaccine against COVID-19Arjun Puranik, Patrick J Lenehan, John C O'Horo, et al.
Medrxiv : the Preprint Server for Health Sciences|December 16, 2022
Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditionsPritha Ghosh, Michiel J M Niesen, Colin Pawlowski, et al.
Iscience|July 31, 2024
Case-control study on post-COVID-19 conditions reveals severe acute infection and chronic pulmonary disease as potential risk factorsPritha Ghosh, Michiel J M Niesen, Colin Pawlowski, et al.
Med (New York, N.Y.)|December 20, 2021
Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infectionArjun Puranik, Patrick J Lenehan, Eli Silvert, et al.
Pageof 9